ロイカフェレシス市場：製品別（デバイス、フィルター、膜分離器）、ロイコパック別（可動化、非可動化）、適応症別（ALL、NHL、多発性骨髄腫）、用途別（研究、治療）、エンドユーザー別（病院、製薬、バイオテクノロジー）、地域別 - 2028年までの世界予測

Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) & Region - Global Forecast to 2028

世界の白血球除去療法製品市場は、年平均成長率8.3%で、2023年の7,000万米ドルから2028年には1億米ドルに達すると予測される。白血球パックの世界市場は、2023年の2億米ドルから2028年には1億2000万米ドルに達す... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年8月31日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	321	338	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界の白血球除去療法製品市場は、年平均成長率8.3%で、2023年の7,000万米ドルから2028年には1億米ドルに達すると予測される。白血球パックの世界市場は、2023年の2億米ドルから2028年には1億2000万米ドルに達すると予測され、CAGRは38.1%である。世界的に白血病患者が増加しており、臨床試験やその他の研究用途でロイコパックのニーズが高まっているため、ロイコフェレーシス市場は予測期間中に成長すると予想される。

"研究用途が白血球除去療法製品市場でより大きなシェアを占める"

用途別では、白血球除去療法製品市場は研究用途と治療用途に区分される。2022年の白血球除去療法製品市場では、研究用途分野がより大きなシェアを占めた。細胞ベースの免疫療法の開発拡大や、医薬品開発における白血球由来の初代細胞に対する需要の高まりは、予測期間中の白血球療法製品市場の成長を促進する主な要因の一部である。

"学術・研究機関セグメントが白血球パクス市場で最大シェアを占める"

エンドユーザー別では、ロイコパクス市場は学術＆研究機関、製薬＆バイオテクノロジー企業、受託研究機関に区分される。2022年には、学術・研究機関セグメントが白血球除去療法製品市場で最大のシェアを占めた。細胞ベースのがん治療に関する研究を実施するための産学連携が増加していることが、このエンドユーザーセグメントの成長を促進している。

"アジア太平洋地域は予測期間中に最も高いCAGRで成長する"

2022年、アジア太平洋地域は予測期間中最高のCAGRで成長する。アジア太平洋地域は予測期間中に最も急成長する地域と予想される。CAR-T細胞療法研究の増加、中国における製薬・バイオ企業や研究機関の増加などが市場成長を促進する要因となっている。2022年、中国はアジア太平洋地域のロイコパックス市場で最大のシェアを占めた。中国のシェアが大きいのは、同国に多くの細胞免疫療法企業が存在することが主因と考えられる。

白血球除去療法製品市場における主要参入企業のプロファイルの内訳供給側
- 企業タイプ別（供給側）：Tier1：35％、Tier2：30％、Tier3：35
- 役職別Cレベル：30％、ディレクターレベル：30％、その他：40%
- 地域別北米：45％、欧州：25％、アジア太平洋地域：20％、その他の地域：10

ロイコパックス市場における主要参入企業プロファイルの内訳供給側
- 企業タイプ別（供給側）ティア1：44%、ティア2：36%、ティア3：20
- 役職別Cレベル：44%、ディレクターレベル：33%、その他：23
- 地域別北米：40％、欧州：25％、アジア太平洋地域：20％、その他の地域：15

白血球除去療法製品市場における主要企業は、旭化成株式会社（日本）、Fresenius SE & Co.KGaA（ドイツ）、Haemonetics Corporation（米国）、Terumo BCT, Inc.（米国）、Macopharma SA（フランス）、Miltenyi Biotec（ドイツ）などが挙げられる。
ロイコパックス市場の有力企業としては、Discovery Life Sciences社（米国）、StemExpress, LLC社（米国）、Charles River Laboratories International, Inc.社（米国）、Caltag Medsystems Limited社（英国）、Lonza Group AG社（スイス）、ZenBio社（米国）などがある。
調査範囲
当レポートでは、白血球除去療法市場を分析し、製品、地域などの様々なセグメントに基づいて、市場規模や今後の成長可能性を推計することを目的としています。また、本市場における主要企業の企業プロフィール、製品提供、最近の動向、主要な市場戦略とともに競合分析も掲載しています。
レポート購入の理由
本レポートは、白血球除去療法市場全体およびサブセグメントにおける収益数の最も近い近似値に関する情報を提供することで、本市場における市場リーダー/新規参入者に役立ちます。本レポートは、利害関係者が競争状況を理解し、より良い事業の位置づけと適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、本レポートは、関係者が市場の鼓動を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供します。

本レポートは、以下のポイントに関する洞察を提供します：

- 主な促進要因（白血病の罹患率および有病率の上昇、献血数の増加、臨床研究におけるロイコパックの需要の増加）、阻害要因（治療用白血球療法およびロイコパックの高コスト、ドナー募集基準の厳格化、治療用白血球療法に伴う合併症）の分析、白血球療法市場の成長に影響を与える機会（小児患者に対する白血球療法、学術機関、製薬・バイオテクノロジー企業、および大手企業からの投資を伴う新興国）、および課題（新興国における輸血の安全性
- 製品開発/イノベーション：白血球除去療法市場における今後の技術、研究開発活動、新製品発売に関する詳細な洞察
- 市場開発：タイプ別、用途別、エンドユーザー別、地域別の有利な新興市場に関する包括的情報。
- 市場の多様化：世界の白血球療法市場における新製品や製品強化、成長地域、最近の開発、投資に関する詳細な情報。
- 競争力の評価：旭化成株式会社（日本）、Fresenius SE & Co.KGaA（ドイツ）、Haemonetics Corporation（米国）、Terumo BCT, Inc.

ページTOPに戻る

1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 38
1.2.1 TYPE 38
1.2.2 APPLICATION 38
1.2.3 END USER 38
1.2.4 INCLUSIONS AND EXCLUSIONS 39
1.3 MARKET SCOPE 40
1.3.1 MARKETS COVERED 40
1.3.2 YEARS CONSIDERED 41
1.4 CURRENCY CONSIDERED 41
TABLE 1 STANDARD CURRENCY CONVERSION RATES 41
1.5 STAKEHOLDERS 41
1.6 SUMMARY OF CHANGES 42
1.7 RECESSION IMPACT 42
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH DATA 43
FIGURE 1 RESEARCH DESIGN 43
2.1.1 SECONDARY DATA 44
2.1.1.1 Key data from secondary sources 45
2.1.2 PRIMARY DATA 45
FIGURE 2 PRIMARY SOURCES 46
2.1.2.1 Key data from primary sources 47
2.1.2.2 Insights from primary experts 48
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS (LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKET) 48
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKAPHERESIS PRODUCTS MARKET) 49
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, AND REGION (LEUKAPHERESIS PRODUCTS MARKET) 49
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKOPAKS MARKET) 50
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, AND REGION (LEUKOPAKS MARKET) 50
2.2 MARKET SIZE ESTIMATION: LEUKAPHERESIS PRODUCTS MARKET 51
FIGURE 8 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 51
FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION: TERUMO CORPORATION (2022) 52
FIGURE 10 REVENUE ANALYSIS OF TOP FOUR COMPANIES: LEUKAPHERESIS PRODUCTS MARKET (2022) 52
FIGURE 11 DEMAND-SIDE APPROACH: LEUKAPHERESIS PRODUCTS MARKET (2022) 53
FIGURE 12 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023–2028) 55
FIGURE 13 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET) 56
FIGURE 14 TOP-DOWN APPROACH 56
2.3 MARKET SIZE ESTIMATION: LEUKOPAKS MARKET 57
FIGURE 15 VOLUME ESTIMATION OF LEUKOPAKS MARKET 58
FIGURE 16 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKOPAKS MARKET) 59
FIGURE 17 TOP-DOWN APPROACH 59
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 61
FIGURE 18 MARKET DATA TRIANGULATION METHODOLOGY 61
2.5 MARKET SHARE ANALYSIS 61
2.6 RESEARCH ASSUMPTIONS 62
2.7 RISK ASSESSMENT 62
TABLE 2 RISK ASSESSMENT: LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKETS 62
2.8 METHODOLOGY-RELATED LIMITATIONS 62
2.9 RECESSION IMPACT ANALYSIS 63
3 EXECUTIVE SUMMARY 64
FIGURE 19 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 64
FIGURE 20 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 65
FIGURE 21 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 65
FIGURE 22 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 66
FIGURE 23 LEUKOPAKS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 67
FIGURE 24 LEUKOPAKS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION) 67
FIGURE 25 LEUKOPAKS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 68
FIGURE 26 GEOGRAPHIC SNAPSHOT: LEUKAPHERESIS PRODUCTS MARKET 69
FIGURE 27 GEOGRAPHIC SNAPSHOT: LEUKOPAKS MARKET 70
4 PREMIUM INSIGHTS 71
4.1 LEUKAPHERESIS PRODUCTS MARKET: OVERVIEW 71
FIGURE 28 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE MARKET 71
4.2 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE AND COUNTRY 72
FIGURE 29 DISPOSABLES TO DOMINATE NORTH AMERICAN LEUKAPHERESIS PRODUCTS MARKET IN 2022 72
4.3 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC MIX 72
FIGURE 30 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 72
4.4 LEUKAPHERESIS PRODUCTS MARKET: REGIONAL MIX 73
FIGURE 31 NORTH AMERICA DOMINATED MARKET IN 2022 73
4.5 LEUKOPAKS MARKET: OVERVIEW 73
FIGURE 32 RISING DEMAND FOR LEUKOPAKS FOR USE IN RESEARCH APPLICATIONS TO DRIVE MARKET 73
4.6 NORTH AMERICA: LEUKOPAKS MARKET, BY PRODUCT AND COUNTRY 74
FIGURE 33 MOBILIZED LEUKOPAKS COMMANDED LARGEST SHARE OF MARKET IN 2022 74
4.7 LEUKOPAKS MARKET: GEOGRAPHIC MIX 75
FIGURE 34 CHINA TO RECORD HIGHEST GROWTH DURING FORECAST PERIOD 75
4.8 LEUKOPAKS MARKET: REGIONAL MIX 75
FIGURE 35 ASIA PACIFIC MARKET TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 75
5 MARKET OVERVIEW 76
5.1 INTRODUCTION 76
5.2 MARKET DYNAMICS 76
FIGURE 36 LEUKAPHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 76
5.2.1 DRIVERS 77
5.2.1.1 Rising incidence and prevalence of leukemia 77
FIGURE 37 ESTIMATED NUMBER OF NEW LEUKEMIA CASES, BY REGION (2020–2040) 77
FIGURE 38 ESTIMATED NUMBER OF LEUKEMIA DEATHS, BY REGION (2020–2040) 78
5.2.1.2 Increasing blood donation 78
5.2.1.3 Growing demand for leukopaks in clinical research 79
FIGURE 39 GROWTH IN NUMBER OF CAR-T CLINICAL TRIALS, 2009–2020 79
FIGURE 40 NUMBER OF CAR-T THERAPY CLINICAL TRIALS: US VS. CHINA, 2022 79
5.2.2 RESTRAINTS 80
5.2.2.1 High cost of therapeutic leukapheresis and leukopaks 80
TABLE 3 COST OF LEUKOPAKS, BY TYPE 80
5.2.2.2 Stringent donor recruitment criteria 81
TABLE 4 DONOR SELECTION CRITERIA 81
TABLE 5 FREQUENCY OF BLOOD DONATION FROM HEALTHY DONORS 82
5.2.2.3 Dearth of skilled professionals 82
5.2.2.4 Complications associated with therapeutic leukapheresis 82
5.2.2.5 Long duration of procedure 82
5.2.2.6 High cost of cellular immunotherapies and lack of favorable reimbursement 83
5.2.3 OPPORTUNITIES 83
5.2.3.1 Growing focus on leukapheresis for pediatric patients 83
5.2.3.2 Increasing investments in CAR-T therapies in emerging economies 84
5.2.3.3 Gaps in current leukapheresis technologies 84
5.2.4 CHALLENGES 84
5.2.4.1 Concerns related to safety of blood transfusion in emerging economies 84
5.3 PORTER’S FIVE FORCES ANALYSIS 85
FIGURE 41 PORTER’S FIVE FORCES ANALYSIS: LEUKAPHERESIS MARKET 85
TABLE 6 LEUKAPHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 85
5.3.1 THREAT FROM NEW ENTRANTS 86
5.3.2 THREAT FROM SUBSTITUTES 86
5.3.3 BARGAINING POWER OF SUPPLIERS 86
5.3.4 BARGAINING POWER OF BUYERS 87
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 87
5.4 INDUSTRY TRENDS 87
5.4.1 INCREASING COLLABORATIONS BETWEEN PHARMA AND BIOTECH COMPANIES 87
TABLE 7 RECENT DEVELOPMENTS RELATED TO CAR-T THERAPY 88
5.4.2 INTRODUCTION OF CUSTOMIZABLE CRYOPRESERVED LEUKOPAKS 89
5.5 TECHNOLOGY ANALYSIS 89
5.5.1 KEY TECHNOLOGIES 89
5.5.1.1 Centrifugal-based leukapheresis 89
5.5.1.2 Membrane-based leukapheresis 90
TABLE 8 MATERIALS USED FOR LEUKOCYTE FILTRATION AND SURFACE MODIFICATION TECHNIQUES APPLIED FOR ENHANCED SEPARATION 90
5.5.2 EMERGING TECHNOLOGIES 90
5.5.2.1 Adsorption-based leukapheresis 90
5.5.2.2 Microfluidic devices for leukapheresis 91
5.5.2.3 Integration of AI in leukapheresis treatment 91
5.6 PRICING ANALYSIS (LEUKOPAKS MARKET) 92
TABLE 9 ASP OF NON-MOBILIZED LEUKOPAKS 92
TABLE 10 ASP OF MOBILIZED LEUKOPAKS 93
TABLE 11 ASP OF MOBILIZED ISOLATED CELLS 93
5.7 KEY CONFERENCES AND EVENTS, 2023–2024 94
TABLE 12 LEUKAPHERESIS MARKET: CONFERENCES AND EVENTS 94
5.8 REGULATORY ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET) 96
5.8.1 NORTH AMERICA 96
5.8.1.1 US 96
5.8.1.2 Canada 96
5.8.2 EUROPE 96
5.8.3 ASIA PACIFIC 97
5.8.3.1 Japan 97
5.8.3.2 China 97
5.9 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99
TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99
TABLE 17 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100
5.10 REGULATORY ANALYSIS (LEUKOPAKS MARKET) 100
5.10.1 US 100
TABLE 18 LIST OF FDA-APPROVED CAR-T THERAPEUTICS 101
5.10.2 EUROPE 101
5.10.3 JAPAN 101
5.10.4 INDIA 102
5.11 VALUE CHAIN ANALYSIS 103
FIGURE 42 VALUE CHAIN: LEUKAPHERESIS MARKET (LEUKAPHERESIS SYSTEMS) 103
5.12 SUPPLY CHAIN ANALYSIS 104
FIGURE 43 LEUKAPHERESIS MARKET: STAKEHOLDERS IN SUPPLY CHAIN 105
5.13 ECOSYSTEM ANALYSIS 105
FIGURE 44 LEUKAPHERESIS MARKET: ECOSYSTEM MAP 105
TABLE 19 LEUKAPHERESIS MARKET: ECOSYSTEM 106
5.14 HS CODES: CENTRIFUGAL DEVICES AND MEMBRANE SEPARATORS 107
5.15 PATENT ANALYSIS 107
5.15.1 PATENT PUBLICATION TRENDS IN LEUKAPHERESIS PRODUCTS MARKET 107
FIGURE 45 GLOBAL PATENT PUBLICATION TRENDS IN LEUKAPHERESIS PRODUCTS MARKET, JANUARY 2019–AUGUST 2023 108
5.15.2 PATENT PUBLICATION TRENDS IN LEUKOPAKS MARKET 108
FIGURE 46 GLOBAL PATENT PUBLICATION TRENDS IN LEUKOPAKS MARKET, JANUARY 2019–AUGUST 2023 108
5.15.3 TOP APPLICANTS FOR LEUKAPHERESIS PRODUCT PATENTS 109
FIGURE 47 TOP APPLICANTS FOR LEUKAPHERESIS PRODUCT PATENTS, JANUARY 2019–AUGUST 2023 109
5.15.4 TOP APPLICANTS FOR LEUKOPAK PATENTS 109
FIGURE 48 TOP APPLICANTS FOR LEUKOPAK PATENTS, JANUARY 2019–AUGUST 2023 109
5.15.5 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKAPHERESIS MARKET PATENTS 110
FIGURE 49 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKAPHERESIS PATENTS, JANUARY 2019–AUGUST 2023 110
FIGURE 50 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKOPAK PATENTS, JANUARY 2019–AUGUST 2023 110
5.15.6 TOP PATENT APPLICANTS/OWNERS 111
FIGURE 51 TOP APPLICANTS AND OWNERS FOR LEUKAPHERESIS PRODUCT PATENTS, JANUARY 2019–AUGUST 2023 111
FIGURE 52 TOP APPLICANTS AND OWNERS FOR LEUKOPAK PATENTS, JANUARY 2019–AUGUST 2023 112
TABLE 20 LEUKAPHERESIS PRODUCTS MARKET: MAJOR PATENTS (2020–2022) 113
TABLE 21 LEUKOPAKS MARKET: MAJOR PATENTS (2019–2022) 115
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 117
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 117
FIGURE 53 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS 117
TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS 117
5.16.2 BUYING CRITERIA 117
FIGURE 54 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS 117
TABLE 23 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS 118
5.17 CASE STUDIES 118
TABLE 24 CASE STUDY 1: ESTIMATING MARKET SIZE OF LEUKAPHERESIS PRODUCTS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL 118
TABLE 25 CASE STUDY 2: ESTIMATING MARKET SIZE OF LEUKOPAKS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL 119
5.18 ADJACENT MARKET ANALYSIS 119
5.18.1 PLASMA FRACTIONATION MARKET 119
FIGURE 55 PLASMA FRACTIONATION MARKET OVERVIEW 119
5.18.2 APHERESIS MARKET 120
FIGURE 56 APHERESIS MARKET OVERVIEW 120
6 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE 121
6.1 INTRODUCTION 122
TABLE 26 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 27 LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
6.2 DISPOSABLES 123
6.2.1 RECURRENT DEMAND TO BOOST SEGMENT 123
TABLE 28 LEUKOREDUCTION FILTER MANUFACTURERS 123
TABLE 29 LEUKAPHERESIS COLUMN AND CELL SEPARATOR MANUFACTURERS 124
TABLE 30 DISPOSABLES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
6.3 DEVICES 125
TABLE 31 DEVICES: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 126
TABLE 32 DEVICES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
6.3.1 CENTRIFUGAL DEVICES 127
6.3.1.1 Increasing installation in hospitals to drive market 127
TABLE 33 CENTRIFUGAL DEVICES AVAILABLE 128
TABLE 34 CENTRIFUGAL DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
6.3.2 MEMBRANE SEPARATORS 129
6.3.2.1 Difficulty in separating large volumes of plasma to limit market 129
TABLE 35 MEMBRANE SEPARATORS AVAILABLE 130
TABLE 36 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 130

7 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION 131
7.1 INTRODUCTION 132
TABLE 37 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 132
7.2 RESEARCH APPLICATIONS 132
7.2.1 GROWING NUMBER OF CLINICAL TRIALS TO DRIVE SEGMENT 132
TABLE 38 COMPANIES DEVELOPING FDA-APPROVED CAR-T CELL THERAPIES 132
TABLE 39 RESEARCH APPLICATIONS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
7.3 THERAPEUTIC APPLICATIONS 134
7.3.1 RISING ADOPTION OF LEUKAPHERESIS FOR LEUKEMIA TREATMENT TO FUEL MARKET 134
TABLE 40 THERAPEUTIC APPLICATIONS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
8 LEUKAPHERESIS PRODUCTS MARKET, BY END USER 135
8.1 INTRODUCTION 136
TABLE 41 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 136
8.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS 136
8.2.1 INCREASING BLOOD DONATION TO DRIVE MARKET 136
TABLE 42 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
8.3 ACADEMIC & RESEARCH INSTITUTES 138
8.3.1 COLLABORATIONS WITH PHARMACEUTICAL COMPANIES TO BOOST MARKET 138
TABLE 43 ACADEMIC & RESEARCH INSTITUTES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 139
8.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE SEGMENT 139
TABLE 44 PHARMA-BIOTECH COMPANIES DEVELOPING CAR-T CELL TECHNOLOGIES 139
TABLE 45 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 141
8.5 HOSPITALS & TRANSFUSION CENTERS 141
8.5.1 GROWING NEED FOR TRANSFUSIONS TO PROPEL MARKET 141
TABLE 46 HOSPITALS & TRANSFUSION CENTERS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 142
9 LEUKOPAKS MARKET, BY TYPE 143
9.1 INTRODUCTION 144
TABLE 47 LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 144
TABLE 48 LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
9.2 MOBILIZED LEUKOPAKS 145
9.2.1 INCREASING USE IN CLINICAL RESEARCH TO DRIVE MARKET 145
TABLE 49 TREATMENT REGIMENS FOR DEVELOPMENT OF MOBILIZED LEUKOPAKS 146
TABLE 50 MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 51 MOBILIZED LEUKOPAKS MARKET, BY REGION, 2021–2028 (UNITS) 147
9.3 NON-MOBILIZED LEUKOPAKS 148
9.3.1 LOW COST TO PROPEL MARKET 148
TABLE 52 NUMBER OF CELLS IN NON-MOBILIZED LEUKOPAKS 148
TABLE 53 COMPARATIVE ANALYSIS OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS 148
TABLE 54 COMPOSITION OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS 149
TABLE 55 NON-MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 149
TABLE 56 NON-MOBILIZED LEUKOPAKS MARKET, BY REGION, 2021–2028 (UNITS) 150
9.4 DISEASED LEUKOPAKS 150
9.4.1 RISING USE FOR CELL INTERACTION AND DRUG TOXICITY STUDIES TO BOOST MARKET 150
TABLE 57 DISEASED LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 58 DISEASED LEUKOPAKS MARKET, BY REGION, 2021–2028 (UNITS) 151
9.5 ISOLATED PBMCS 152
9.5.1 INCREASING RESEARCH FOCUS ON CELL-BASED THERAPIES TO FUEL MARKET 152
TABLE 59 IMMUNE CELL TYPES AND TARGETED DISEASES 152
TABLE 60 ISOLATED PBMCS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 61 ISOLATED PBMCS MARKET, BY REGION, 2021–2028 (UNITS) 153
10 LEUKOPAKS MARKET, BY INDICATION 154
10.1 INTRODUCTION 155
FIGURE 57 NUMBER OF GLOBAL CLINICAL TRIALS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) CELLS 155
TABLE 62 LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 156
10.2 ACUTE LYMPHOCYTIC LEUKEMIA 157
10.2.1 RISING INCIDENCE OF DISEASE TO DRIVE MARKET 157
TABLE 63 ACUTE LYMPHOCYTIC LEUKEMIA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 158
10.3 MULTIPLE MYELOMA 158
10.3.1 RISING DIAGNOSIS RATE TO FUEL SEGMENT 158
FIGURE 58 INCIDENCE OF MULTIPLE MYELOMA IN 2020 159
TABLE 64 MULTIPLE MYELOMA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 159
10.4 NON-HODGKIN’S LYMPHOMA 160
10.4.1 DEVELOPMENT OF NOVEL THERAPIES TO BOOST MARKET 160
TABLE 65 NON-HODGKIN’S LYMPHOMA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 161
10.5 CHRONIC LYMPHOCYTIC LEUKEMIA 161
10.5.1 RISING NUMBER OF CASES TO PROPEL MARKET 161
TABLE 66 CHRONIC LYMPHOCYTIC LEUKEMIA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 162
10.6 PANCREATIC CANCER 162
10.6.1 DEVELOPMENT OF NEW DIAGNOSTIC TECHNIQUES TO DRIVE SEGMENT 162
FIGURE 59 INCIDENCE OF PANCREATIC CANCER IN 2020 163
TABLE 67 PANCREATIC CANCER: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 164
10.7 HEPATOCELLULAR CARCINOMA 164
10.7.1 INCREASING INCIDENCE OF VIRAL HEPATITIS TO FUEL SEGMENT 164
TABLE 68 HEPATOCELLULAR CARCINOMA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 165
10.8 OTHER INDICATIONS 165
TABLE 69 OTHER INDICATIONS: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 166
11 LEUKOPAKS MARKET, BY END USER 167
11.1 INTRODUCTION 168
TABLE 70 LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 168
11.2 ACADEMIC & RESEARCH INSTITUTES 168
11.2.1 INCREASING INDUSTRY−ACADEMIC RESEARCH PARTNERSHIPS TO DRIVE MARKET 168
TABLE 71 ACADEMIC & RESEARCH INSTITUTES: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 169
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 169
11.3.1 RISING DEMAND FOR TARGET DRUG DEVELOPMENT TO PROPEL MARKET 169
FIGURE 60 PERCENTAGE OF GLOBAL CAR-T DRUGS IN US AND CHINA, BY YEAR OF FIRST IDENTIFICATION/REPORT 170
TABLE 72 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 170
11.4 CONTRACT RESEARCH ORGANIZATIONS 171
11.4.1 INCREASING CLINICAL TRIAL SPONSORSHIP TO DRIVE MARKET 171
TABLE 73 CONTRACT RESEARCH ORGANIZATIONS: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 171
12 LEUKAPHERESIS MARKET, BY REGION 172
12.1 INTRODUCTION 173
FIGURE 61 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 173
TABLE 74 LEUKAPHERESIS PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 174
FIGURE 62 LEUKOPAKS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 174
TABLE 75 LEUKOPAKS MARKET, BY REGION, 2021–2028 (USD MILLION) 175
12.2 NORTH AMERICA 175
12.2.1 RECESSION IMPACT: NORTH AMERICA 175
FIGURE 63 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT 176
TABLE 76 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 77 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 78 NORTH AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 79 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 178
TABLE 80 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 178
TABLE 81 NORTH AMERICA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 82 NORTH AMERICA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 179
TABLE 83 NORTH AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 179
TABLE 84 NORTH AMERICA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 180
12.2.2 US 180
12.2.2.1 Presence of leading pharmaceutical and biotechnology companies to drive market 180
TABLE 85 DIAGNOSIS-RELATED GROUP REIMBURSEMENT (DRG) 180
TABLE 86 US: KEY MACROINDICATORS 181
TABLE 87 US: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 88 US: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 89 US: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 182
TABLE 90 US: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 182
TABLE 91 US: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 182
TABLE 92 US: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 183
TABLE 93 US: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 183
12.2.3 CANADA 183
12.2.3.1 Rising prevalence of blood cancer to stimulate market growth 183
TABLE 94 CANADA: KEY MACROINDICATORS 184
TABLE 95 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 96 CANADA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 97 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 185
TABLE 98 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 185
TABLE 99 CANADA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 186
TABLE 100 CANADA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 186
TABLE 101 CANADA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 187

12.3 EUROPE 187
12.3.1 RECESSION IMPACT: EUROPE 188
FIGURE 64 EUROPE: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT 189
TABLE 102 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 190
TABLE 103 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 104 EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 105 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 191
TABLE 106 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 191
TABLE 107 EUROPE: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 192
TABLE 108 EUROPE: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 109 EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 193
TABLE 110 EUROPE: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 193
12.3.2 UK 193
12.3.2.1 Rising awareness of cell-based therapies to propel market 193
TABLE 111 UK: KEY MACROINDICATORS 194
TABLE 112 UK: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 194
TABLE 113 UK: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 114 UK: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 195
TABLE 115 UK: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 195
TABLE 116 UK: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 117 UK: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 196
TABLE 118 UK: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 197
12.3.3 GERMANY 197
12.3.3.1 Increasing research on cancer immunotherapies to boost market 197
TABLE 119 GERMANY: KEY MACROINDICATORS 197
TABLE 120 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 121 GERMANY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 122 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 198
TABLE 123 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 199
TABLE 124 GERMANY: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 199
TABLE 125 GERMANY: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 200
TABLE 126 GERMANY: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 200
12.3.4 SPAIN 200
12.3.4.1 Rising focus on development of novel CAR-T cell therapies to fuel market 200
TABLE 127 SPAIN: KEY MACROINDICATORS 201
TABLE 128 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 129 SPAIN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 130 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 202
TABLE 131 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 202
TABLE 132 SPAIN: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 133 SPAIN: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 203
TABLE 134 SPAIN: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 203
12.3.5 FRANCE 203
12.3.5.1 Government healthcare initiatives to drive market 203
TABLE 135 FRANCE: KEY MACROINDICATORS 204
TABLE 136 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 204
TABLE 137 FRANCE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 204
TABLE 138 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 205
TABLE 139 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 205
TABLE 140 FRANCE: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 141 FRANCE: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 206
TABLE 142 FRANCE: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 206
12.3.6 ITALY 206
12.3.6.1 Increasing adoption of cell-based therapies to boost market 206
TABLE 143 ITALY: COMMERCIAL CAR-T CELL THERAPIES APPROVED BY EMA (2022) 207
TABLE 144 ITALY: KEY MACROINDICATORS 207
TABLE 145 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 146 ITALY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 147 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 208
TABLE 148 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 209
TABLE 149 ITALY: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 209
TABLE 150 ITALY: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 210
TABLE 151 ITALY: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 210
12.3.7 REST OF EUROPE 210
TABLE 152 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 153 REST OF EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 154 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 212
TABLE 155 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 212
TABLE 156 REST OF EUROPE: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 212
TABLE 157 REST OF EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 213
TABLE 158 REST OF EUROPE: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 213
12.4 ASIA PACIFIC 214
12.4.1 RECESSION IMPACT: ASIA PACIFIC 214
FIGURE 65 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT 215
TABLE 159 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 216
TABLE 160 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 216
TABLE 161 ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 216
TABLE 162 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 217
TABLE 163 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 217
TABLE 164 ASIA PACIFIC: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 218
TABLE 165 ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 218
TABLE 166 ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 219
TABLE 167 ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 219
12.4.2 CHINA 219
12.4.2.1 Growing awareness of benefits of leukapheresis to drive market 219
FIGURE 66 CHINA: NUMBER OF CAR-T BASED CLINICAL TRIALS REGISTERED (2013–2020) 220
TABLE 168 CHINA: KEY MACROINDICATORS 220
TABLE 169 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 221
TABLE 170 CHINA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 221
TABLE 171 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 221
TABLE 172 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 222
TABLE 173 CHINA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 222
TABLE 174 CHINA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 223
TABLE 175 CHINA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 223
12.4.3 JAPAN 223
12.4.3.1 Focus on development of cell therapies to boost market 223
TABLE 176 JAPAN: KEY MACROINDICATORS 224
TABLE 177 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 178 JAPAN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 179 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 225
TABLE 180 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 225
TABLE 181 JAPAN: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 225
TABLE 182 JAPAN: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 226
TABLE 183 JAPAN: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 226
12.4.4 INDIA 227
12.4.4.1 Rising government investment in healthcare to drive market growth 227
TABLE 184 INDIA: KEY MACROINDICATORS 227
TABLE 185 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 227
TABLE 186 INDIA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 187 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 228
TABLE 188 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 228
TABLE 189 INDIA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 229
TABLE 190 INDIA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 229
TABLE 191 INDIA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 230
12.4.5 AUSTRALIA 230
12.4.5.1 Increasing incidence of blood cancer to drive market 230
TABLE 192 AUSTRALIA: KEY MACROINDICATORS 231
TABLE 193 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 231
TABLE 194 AUSTRALIA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 231
TABLE 195 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 232
TABLE 196 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 232
TABLE 197 AUSTRALIA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 232
TABLE 198 AUSTRALIA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 233
TABLE 199 AUSTRALIA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 233
12.4.6 SOUTH KOREA 234
12.4.6.1 Increasing research in cell therapy to fuel market growth 234
TABLE 200 SOUTH KOREA: KEY MACROINDICATORS 234
TABLE 201 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 234
TABLE 202 SOUTH KOREA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 235
TABLE 203 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 235
TABLE 204 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 235
TABLE 205 SOUTH KOREA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 236
TABLE 206 SOUTH KOREA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 236
TABLE 207 SOUTH KOREA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 237
12.4.7 REST OF ASIA PACIFIC 237
TABLE 208 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 237
TABLE 209 REST OF ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 210 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 238
TABLE 211 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 238
TABLE 212 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 239
TABLE 213 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 239
TABLE 214 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 240
12.5 LATIN AMERICA 240
12.5.1 RECESSION IMPACT: LATIN AMERICA 240
TABLE 215 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 241
TABLE 216 LATIN AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 241
TABLE 217 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 241
TABLE 218 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 242
TABLE 219 LATIN AMERICA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 242
TABLE 220 LATIN AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 243
TABLE 221 LATIN AMERICA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 243

12.6 MIDDLE EAST & AFRICA 244
12.6.1 RECESSION IMPACT: MIDDLE EAST & AFRICA 244
TABLE 222 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 244
TABLE 223 MIDDLE EAST & AFRICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 245
TABLE 224 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 245
TABLE 225 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 245
TABLE 226 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 246
TABLE 227 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 246
TABLE 228 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 247

ページTOPに戻る

Table of Contents

Summary

The global leukapheresis products market is predicted to reach USD 100 million by 2028 from USD 70 million in 2023, at a CAGR of 8.3%. The global leukopaks market is predicted to reach USD 1020 million by 2028 from USD 200 million in 2023, at a CAGR of 38.1%. Due to the cases of leukemia rising globally, and rising need for leukopaks in clinical trials and other research applications, the leukapheresis market is expected to grow in the forecast period.

“The research applications accounted for a larger share of the leukapheresis products market.”

By, application, the leukpaheresis products market is segmented into research applications and therapeutic applications. The research applications segment accounted for the larger share of the leukapheresis products market in 2022. The growing development of cell-based immunotherapies and rising demand for leukapheresis-derived primary cells in drug development are some of the major factors driving the growth of the leukapheresis products market during the forecast period.

“The academic & research institutes segment accounted for the largest share of the leukopaks market.”

By end user, the leukopaks market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations. In 2022, the academic & research institutes segment accounted for the largest share of the leukapheresis products market. The increasing number of industry-academic partnerships for conducting research on cell-based cancer therapies is driving the growth of this end-user segment.

“Asia Pacific will grow at highest CAGR during the forecast period.“

In 2022, Asia Pacific will grow at highest CAGR during the forecast period. The Asia Pacific region is expected to be the fastest growing region in the forecast period. The increasing CAR-T cell therapy research and rising number of pharma & biotech companies and research institutes in China are some of the factors driving market growth. In 2022, China accounted for the largest share of the Asia Pacific leukopaks market. The large share of China can be attributed mainly to the presence of a number of cellular immunotherapy companies in the country.

The break-up of the profile of primary participants in the leukapheresis products market: Supply-side
• By Company Type (Supply-side): Tier 1: 35%, Tier 2: 30%, and Tier 3: 35%
• By Designation: C-level: 30%, Director-level: 30%, and Others: 40%
• By Region: North America: 45%, Europe: 25%, Asia-Pacific: 20%, and Rest of the World: 10%

The break-up of the profile of primary participants in the leukopaks market: Supply-side
• By Company Type (Supply-side): Tier 1: 44%, Tier 2: 36%, and Tier 3: 20%
• By Designation: C-level: 44%, Director-level: 33%, and Others: 23%
• By Region: North America: 40%, Europe: 25%, Asia-Pacific: 20%, and Rest of the World: 15%

Prominent players in the leukapheresis products market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany).
Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US).
Research Coverage:
The report analyzes the leukapheresis market and aims at estimating the market size and future growth potential of this market based on various segments such as product, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall leukapheresis market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

• Analysis of key drivers (rising incidence and prevalence of leukemia, increasing number of blood donations, increased demand for leukopaks in clinical research), restraints (high cost of therapeutic leukapheresis and leukopaks, stringent donor recruitment criteria, complications associated with therapeutic leukapheresis), opportunities (leukapheresis for pediatric patients, emerging economies with investments from academic institutes, pharma-biotech companies, and leading players), and challenges (blood transfusion safety in emerging countries) influencing the growth of the leukapheresis market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the leukapheresis market
• Market Development: Comprehensive information on the lucrative emerging markets by type, usage, end user and region.
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global leukapheresis market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players like Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany) in the global leukapheresis market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療機器）の最新刊レポート

MarketsandMarkets社のMedical Devices分野での最新刊レポート

本レポートと同じKEY WORD（devices）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療機器）の最新刊レポート

MarketsandMarkets社のMedical Devices分野での最新刊レポート

本レポートと同じKEY WORD（devices）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?